January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
June 2025 in “British Journal of Dermatology” Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
February 2014 in “Revista Argentina de Cardiología” Androgens may increase arrhythmias in Brugada Syndrome, while Finasteride could reduce them.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
11 citations
,
January 2021 in “Breast Care” Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
136 citations
,
January 2013 in “International Journal of Trichology”
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
May 2023 in “Journal of Applied Cosmetology” The Annurca apple supplement significantly improved hair growth in people with hair loss.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
April 2019 in “Journal of the Endocrine Society” A 12-year-old boy with PAIS successfully developed male characteristics using high-dose testosterone and anastrozole.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
4 citations
,
December 2024 in “Archives of Dermatological Research” 44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
34 citations
,
April 1982 in “BMJ” January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
Baricitinib works better than methotrexate for severe alopecia areata.